179 related articles for article (PubMed ID: 31010234)
1. Dual Targeting of Y-Box Binding Protein-1 and Akt Inhibits Proliferation and Enhances the Chemosensitivity of Colorectal Cancer Cells.
Maier E; Attenberger F; Tiwari A; Lettau K; Rebholz S; Fehrenbacher B; Schaller M; Gani C; Toulany M
Cancers (Basel); 2019 Apr; 11(4):. PubMed ID: 31010234
[TBL] [Abstract][Full Text] [Related]
2. Stress-Induced Phosphorylation of Nuclear YB-1 Depends on Nuclear Trafficking of p90 Ribosomal S6 Kinase.
Tiwari A; Rebholz S; Maier E; Dehghan Harati M; Zips D; Sers C; Rodemann HP; Toulany M
Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30126195
[TBL] [Abstract][Full Text] [Related]
3. Fisetin overcomes non-targetability of mutated KRAS induced YB-1 signaling in colorectal cancer cells and improves radiosensitivity by blocking repair of radiation-induced DNA double-strand breaks.
Khozooei S; Veerappan S; Bonzheim I; Singer S; Gani C; Toulany M
Radiother Oncol; 2023 Nov; 188():109867. PubMed ID: 37634766
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous Targeting of RSK and AKT Efficiently Inhibits YB-1-Mediated Repair of Ionizing Radiation-Induced DNA Double-Strand Breaks in Breast Cancer Cells.
Lettau K; Zips D; Toulany M
Int J Radiat Oncol Biol Phys; 2021 Feb; 109(2):567-580. PubMed ID: 32931865
[TBL] [Abstract][Full Text] [Related]
5. Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells.
Stratford AL; Fry CJ; Desilets C; Davies AH; Cho YY; Li Y; Dong Z; Berquin IM; Roux PP; Dunn SE
Breast Cancer Res; 2008; 10(6):R99. PubMed ID: 19036157
[TBL] [Abstract][Full Text] [Related]
6. Blocking Y-Box Binding Protein-1 through Simultaneous Targeting of PI3K and MAPK in Triple Negative Breast Cancers.
Tiwari A; Iida M; Kosnopfel C; Abbariki M; Menegakis A; Fehrenbacher B; Maier J; Schaller M; Brucker SY; Wheeler DL; Harari PM; Rothbauer U; Schittek B; Zips D; Toulany M
Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 33003386
[TBL] [Abstract][Full Text] [Related]
7. Luteolin is a novel p90 ribosomal S6 kinase (RSK) inhibitor that suppresses Notch4 signaling by blocking the activation of Y-box binding protein-1 (YB-1).
Reipas KM; Law JH; Couto N; Islam S; Li Y; Li H; Cherkasov A; Jung K; Cheema AS; Jones SJ; Hassell JA; Dunn SE
Oncotarget; 2013 Feb; 4(2):329-45. PubMed ID: 23593654
[TBL] [Abstract][Full Text] [Related]
8. Targeting ribosomal S6 kinases/Y-box binding protein-1 signaling improves cellular sensitivity to taxane in prostate cancer.
Shiota M; Itsumi M; Yokomizo A; Takeuchi A; Imada K; Kashiwagi E; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
Prostate; 2014 Jun; 74(8):829-38. PubMed ID: 24729449
[TBL] [Abstract][Full Text] [Related]
9. MKNK1 is a YB-1 target gene responsible for imparting trastuzumab resistance and can be blocked by RSK inhibition.
Astanehe A; Finkbeiner MR; Krzywinski M; Fotovati A; Dhillon J; Berquin IM; Mills GB; Marra MA; Dunn SE
Oncogene; 2012 Oct; 31(41):4434-46. PubMed ID: 22249268
[TBL] [Abstract][Full Text] [Related]
10. ERK/RSK-mediated phosphorylation of Y-box binding protein-1 aggravates diabetic cardiomyopathy by suppressing its interaction with deubiquitinase OTUB1.
Zhong X; Wang T; Zhang W; Wang M; Xie Y; Dai L; He X; Madhusudhan T; Zeng H; Wang H
J Biol Chem; 2022 Jun; 298(6):101989. PubMed ID: 35490780
[TBL] [Abstract][Full Text] [Related]
11. Targeting p90 ribosomal S6 kinase eliminates tumor-initiating cells by inactivating Y-box binding protein-1 in triple-negative breast cancers.
Stratford AL; Reipas K; Hu K; Fotovati A; Brough R; Frankum J; Takhar M; Watson P; Ashworth A; Lord CJ; Lasham A; Print CG; Dunn SE
Stem Cells; 2012 Jul; 30(7):1338-48. PubMed ID: 22674792
[TBL] [Abstract][Full Text] [Related]
12. Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model.
Alamo P; Gallardo A; Di Nicolantonio F; Pavón MA; Casanova I; Trias M; Mangues MA; Lopez-Pousa A; Villaverde A; Vázquez E; Bardelli A; Céspedes MV; Mangues R
FASEB J; 2015 Feb; 29(2):464-76. PubMed ID: 25359494
[TBL] [Abstract][Full Text] [Related]
13. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E
J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487
[TBL] [Abstract][Full Text] [Related]
14. Human melanoma cells resistant to MAPK inhibitors can be effectively targeted by inhibition of the p90 ribosomal S6 kinase.
Kosnopfel C; Sinnberg T; Sauer B; Niessner H; Schmitt A; Makino E; Forschner A; Hailfinger S; Garbe C; Schittek B
Oncotarget; 2017 May; 8(22):35761-35775. PubMed ID: 28415756
[TBL] [Abstract][Full Text] [Related]
15. RSK-mediated nuclear accumulation of the cold-shock Y-box protein-1 controls proliferation of T cells and T-ALL blasts.
Gieseler-Halbach S; Meltendorf S; Pierau M; Weinert S; Heidel FH; Fischer T; Handschuh J; Braun-Dullaeus RC; Schrappe M; Lindquist JA; Mertens PR; Thomas U; Brunner-Weinzierl MC
Cell Death Differ; 2017 Feb; 24(2):371-383. PubMed ID: 28009354
[TBL] [Abstract][Full Text] [Related]
16. Resistance to Selumetinib (AZD6244) in colorectal cancer cell lines is mediated by p70S6K and RPS6 activation.
Grasso S; Tristante E; Saceda M; Carbonell P; Mayor-López L; Carballo-Santana M; Carrasco-García E; Rocamora-Reverte L; García-Morales P; Carballo F; Ferragut JA; Martínez-Lacaci I
Neoplasia; 2014 Oct; 16(10):845-60. PubMed ID: 25379021
[TBL] [Abstract][Full Text] [Related]
17. YB-1 activating cascades as potential targets in KRAS-mutated tumors.
Khozooei S; Veerappan S; Toulany M
Strahlenther Onkol; 2023 Dec; 199(12):1110-1127. PubMed ID: 37268766
[TBL] [Abstract][Full Text] [Related]
18. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.
Tejpar S; Celik I; Schlichting M; Sartorius U; Bokemeyer C; Van Cutsem E
J Clin Oncol; 2012 Oct; 30(29):3570-7. PubMed ID: 22734028
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of microRNA-135b and microRNA-182 promotes chemoresistance of colorectal cancer by targeting ST6GALNAC2 via PI3K/AKT pathway.
Liu B; Liu Y; Zhao L; Pan Y; Shan Y; Li Y; Jia L
Mol Carcinog; 2017 Dec; 56(12):2669-2680. PubMed ID: 28767179
[TBL] [Abstract][Full Text] [Related]
20. CCR7 high expression leads to cetuximab resistance by cross-talking with EGFR pathway in PI3K/AKT signals in colorectal cancer.
Gao L; Xu J; He G; Huang J; Xu W; Qin J; Zheng P; Ji M; Chang W; Ren L; Wei Y; Xu J; Liang C
Am J Cancer Res; 2019; 9(11):2531-2543. PubMed ID: 31815051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
